pfizer glp 1 drug The next breakthrough in weight-loss medicine may not be a stronger drug. It may simply be a people are more likely to keep taking. Pfizer's experimental obesity treatment, berobenatide, could reduce Pfizer pulls out of GLP-1

In this review, we highlight current clinical trials in neurological disorders and conclude by discussing therapeutic opportunities and challenges for sulforaphane

The well established sarcopenia associated with older age seems to be associated in part to a decline in protein and energy intake, caused by changes in taste sensation, alterations in dentition, social isolation, depression and economic factors

The gap between biohacker enthusiasm and clinical evidence remains vast, but specific compounds merit continued attention for prevention-focused research

For anyone exploring neuroprotective peptide strategies , understanding the BDNF-neurodegeneration connection is foundational